Project Grant HT94252510129
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$773K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The Department of Defense's Defense Health Agency awarded a $263,598 project grant to Brigham & Women's Hospital Inc. in Boston, MA to conduct research for the "LAM-TARGETING NANOPARTICLE-ASSISTED AND BASE EDITOR-ENABLED GENE THERAPY FOR LYMPHANGIOLEIOMYOMATOSIS" project. This 24-month grant, which runs from August 1, 2024 to July 31, 2026, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to develop novel gene therapy...
This federal Project Grant award of $855,709.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Brigham & Women's Hospital Inc. to target mitochondrial metabolism in Tuberous Sclerosis Complex. The 3-year project, running from September 1, 2023 to August 31, 2026, aims to transform healthcare for Service Members and the American public through innovative and impactful biomedical research on this rare...
This federal Project Grant award of $793,572.00, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a novel translational research study investigating the underlying pathophysiology of tuberous sclerosis complex (TSC) at Brigham & Women's Hospital. The award, with a performance period from August 2024 to August 2027, will fund cutting-edge research aimed at developing a better understanding of the mechanisms driving TSC,...
The federal Project Grant award for $236,072 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to evaluate the efficacy of novel B7-H3 antibodies in tuberous sclerosis complex (TSC). The awardee, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will conduct this biomedical research project over a 2-year period from August 1, 2024 to July 31, 2026. As a leading academic medical center, Brigham...
Brigham & Women's Hospital Inc. was awarded a $379,876 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 through August 31, 2026 to investigate whether microbiome-derived cell fragments in the brain can accelerate the transition from traumatic brain injury to Alzheimer's disease or related dementias. As the direct awardee, Brigham & Women's Hospital will leverage...
This federal Project Grant award of $1,683,194.00 was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Brigham & Womens Hospital Inc., a prominent academic medical center and research institution affiliated with Harvard Medical School. The award supports advanced biomedical research focused on the role of the glycome in tuberous sclerosis complex (TSC) biomarker identification and molecular pathogenesis. The research aims to...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...